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Abstract 
In this study, the in vitro stability of cisplatin (CisPt) and cationic platinum(II)-complex (caPt(II)-complex) and their in 
vitro activity (antiproliferative and anti-angiogenic properties) were investigated against three aggressive human tumor 
cell lines. caPt(II)-complex shown a high stability until 9 days of treatment and displayed a significant and higher activity 
than CisPt against both NCI-H28 mesothelioma (19.37 ± 9.57 µM versus 34.66 ± 7.65 µM for CisPt) and U87 MG 
glioblastoma (19.85 ± 0.97 µM versus 54.14 ± 3.19 for CisPt). Mesenchymal Stromal Cells (AT-MSCs) showed a 
significant different sensitivity (IC50= 71.9 ± 15.1 µM for caPt(II)-complex and 8.7 ± 4.5 µM for CisPt) to the 
antiproliferative activity of caPt(II)-complex and CisPt. The ability of MSCs to uptake both the drugs in a similar amount 
of 2.49 pM /cell, suggested a possible development of new therapies based on cell mediated drug delivery.  
Keywords: Cisplatin, Cationic platinum (II)-complex, mesothelioma, glioblastoma, mesenchymal stromal cells, drug 
delivery. 
1. Introduction 
In the last decades the field of cancer therapeutic treatment has been marked by important advancements thanks to the 
introduction of new surgical procedures and new chemotherapeutic drugs. Unfortunately, the 4th most common cause 
of cancer-related death is due to three different tumors still lacking for a proper response: malignant pleural 
mesothelioma (MPM),[1] glioblastoma multiforme (GBM)[2] and pancreatic adenocarcinoma (PAC)[3]. These types of 
solid tumor are in fact difficult to defeat because they spread aggressively and resulted highly resistant to conventional 
chemotherapeutic agents other than the fact that they exhibited a high propensity to recur.  
MPM is a malignant neoplasm of the pleura related to asbestos exposure. It tends to grow over the serosal surface and 
finally encases the lung, causing death by asphyxiation. Currently the standard first-line treatment is a platinum-based 
doublet containing a third-generation antifolate like pemetrexed (PMX) but any second-line treatments for MPM has 
been approved yet.[4-6]  
GBM is a highly malignant and aggressive primary brain tumor. Despite of an arsenal of therapeutic interventions, the 
prognosis of glioblastoma remains very poor. Cisplatin based therapy is one of the most important chemotherapy 
treatments for GBM and it is repurposed as the second line against GBM albeit its efficacy is limited by drug resistance 
and undesirable side effects including neurotoxicity that limits its efficacy.[7, 8] 
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PAC has recently emerged as one of the most aggressive tumors with a death rate that has remained relatively stable in 
the last ten years, thus providing a limited progress in this field. In the treatment of pancreatic cancer, platinum 
derivatives are frequently used in combination schedules with gemcitabine (GCB) in several phase II trials.[9, 10] 
These tumors remain some of the most lethal thus evoking the need for new therapeutic treatments in order to improve 
patient survival and quality of life. To date, the use of platinum drugs for the treatment of these pathologies has shown 
minimal success mainly due to a failure in the delivery to the tumor site so that high doses of the platinum 
chemotherapeutic agent is required for a positive response to the therapy. Over the last thirty years, the research field 
of platinum anticancer drugs has experienced an extensive development with the recognition of the potential anticancer 
activity of platinum compounds whose novel structural properties developed for active platinum drugs allowed to 
enlarge the spectrum of activity, to overcome cellular resistance and to lower toxicity. In this regard, violating the 
apparently demanded neutrality, many cationic monofunctional platinum-based anticancer agents were synthetized and 
characterized.[11] This focusing is because, in comparison with the bifunctional cisplatin, monofunctional compounds 
display a distinct mechanism of action and a different antitumor profile taking into consideration their ability to 
effectively bind to DNA and to inhibit transcription both in vitro and in vivo. They are often characterized by the general 
formula cis-[Pt(NH3)2(L)Cl]+, where L is an N-heterocycle and the choice for L is usually for a small N-heterocyclic 
amine ligand with a molecular weight less than 200, such as pyridine (for pyriplatin) or phenanthridine (for 
phenanthriplatin). Indeed, the choice of the N-heterocycle ligand has been suggested as the main responsible for 
determining the anticancer activity spectrum and the relative mechanism of monofunctional platinum complexes.[12] 
Upon the above premises, many cationic platinum complexes have been identified with different biological behavior as 
compared to cisplatin but endowed with equivalent or higher potential to kill cancerous cells.[13] 
Recently, our research group has synthesized a series of cationic bulky triamine platinum compounds of general formula 
[Pt(N-N’)N’Cl]X- where N-N’ is an aminomethylimidazole ligand[14] and the N’ an imidazole ring, both bearing the same 
alkyl group at the N1 position. Notably, when the alkyl group is a long linear carbon chain (C6) as in complex 2c, the 
cationic platinum (II) compound showed a very effective and potent cytotoxic effect in triple-negative breast cancer cells 
and in cell lines partially resistant to cisplatin.[15] Its cytotoxic capability closed to its completely different 
pharmacodynamic and cellular uptake behavior than cisplatin, makes it as a valid candidate for evaluating cytotoxicity 
in these three tumor cell lines. 
 
Scheme 1. Cationic platinum(II)-complex (caPt(II)-complex) 
As previously reported mesenchymal stromal cells (MSCs) from different tissues are able to uptake drugs (eg.: Paclitaxel, 
Gemcitabine, Doxorubicin et al.)[16-20] and release them both as free molecule and exosome associated drugs.[21] The 
drug is released in vitro in amounts effective against cancer cells and also in vivo the drug loaded MSCs may be used as 
a physiological tool for drug delivery by injecting them both in situ and by systemic way.[22] These characteristics of 
MSCs suggest new strategies to apply in advanced cell therapy, in particular for treating cancer. Their potential 
application is in part depending on the solubility of the drug in medium and their stability during the drug loading 
procedure. The same platinum-based drugs have very limited solubility in culture medium and also can suffer 
degradation process by pH modification and temperature.[23] The present study evaluated these biological 
characteristics of platinum based drugs by comparing a new cationic platinum(II) complex (caPt (II)-complex) to 
cisplatin (CisPt). Our results evidenced that caPt (II)-complex has a very high stability when incubated at 37 °C in cell 
culture medium and that its in vitro activity against glioblastoma and mesothelioma was significantly higher than that 
exerted by CisPt. We also demonstrated that caPt (II)-complex can be easy incorporate and release by MSCs without 
loss of its anticancer activity.  
2. Materials & Methods 
2.1. Drugs and tumor cell lines  
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Rates of Cisplatin (CisPt) and caPt (II)-complex were prepared at the concentration of 4 mg/ml in dimethyl sulfoxide 
(DMSO, Sigma-Aldrich, USA). Working solutions were freshly prepared according to the experimental design by serial 
dilutions in complete culture medium. The chemotherapeutic drug Paclitaxel (PTX, kindly provided by Freseneius-Kabi, 
Italy; stock solution for infusion 6 mg/ml), was used as standard drug for antiproliferation assays. The in vitro activity 
of CisPt, caPt (II)-complex and PTX was tested against three tumor cell lines: malignant pleural mesothelioma (MPM) 
cell line NCI-H28[24], glioblastoma cell line U87 MG[25] and  pancreatic adenocarcinoma cell line CFPAC-1,[26] used 
as laboratory standard cancer cell line. Cells lines were maintained by 1:5 weekly dilution in Roswell Park Memorial 
Institute medium (RPMI) medium (NCIH28), Dulbecco's Modified Eagle (DMEM LG) medium (U87 MG) and Iscove's 
Modified Dulbecco's Medium (IMDM) medium (CFPAC-1), supplemented by Foetal bovine serum (FBS) 10%. All 
reagents for culture were provided by Euroclone, UK. 
 
2.2. Adipose Tissue Mesenchymal stromal cells (AT-MSCs) 
As starting biological material were used lipoaspirate samples of adult donors after signed informed consent of no 
objection for the use for research of surgical tissues (otherwise destined for destruction) in accordance with the 
Declaration of Helsinki. The approval for their use was obtained from the Institutional Ethical Committee of Milan 
University (n.59/15, C.E. UNIMI, 09.1115).  The Adipose Tissue Mesenchymal stromal cells (AT-MSCs) were isolated 
from 20 ml of lipoaspirate processed as previously described by using Lipogems device (Lipogems® International 
Spa)[27] and 2 ml for a sample of lipogems (LG) were processed for MSC isolation as previously described.[28] Briefly, 
the sample was disaggregated by enzymatic digestion with 200 U/ml of collagenase tipe I (Life technologies, USA), then 
was centrifuged (1000xg, 15 min) and the floating fraction was separated from the cellular pellet. Cellular pellet was 
plated on 25cm2 flask (Euroclone, UK) and expanded in StemMACS medium (Miltenyi Biotec, Germany) until passage 
3. Primary cultures were analyzed for their proliferation rate (Population doubling time), clonogenicity (CFU-F assay), 
expression of the typical mesenchymal stem cell markers and multi-differentiative ability towards mesodermal lineages 
(osteogenic, adipogenic and chondrogenic differentiation). 
 
2.3. Drug sensitivity of tumor cells and AT-MSCs to Cisplatin (CisPt), caPt (II)-complex and PTX 
The effect of CisPt and caPt (II)-complex against cell proliferation has been studied in 96 multiwell plates (Sarstedt, 
Germany). Briefly, 1:2 serial dilutions of pure drug (from 0.15 to 20 µg/ml) were prepared in 100 µl of culture 
medium/well and then to each well were added 2,000 tumor cells. As standard internal positive control, the sensitivity 
of tumor cells to paclitaxel (PTX) were determined by adding the drugs at increasing two folds concentrations from 0.78 
to 50 ng/ml. After 7 days of culture (anti-proliferative assay) at 37°C and 5% CO2, cell growth was evaluated by MTT 
assay (3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium) as previously described.[29, 30] Against AT-MSCs, 
also cytotoxicity assay (24 hours at 37°C, 5% CO2) was performed at increasing concentrations of 0.8, 4, 20, 25, 50, 75, 
100 μg/ml. The inhibitory concentration (IC50) was determined according to the Reed & Muench formula.[31] AT-MSCs 
were treated for 24 hours with 75 µM CisPt or CaPt(II) complex respectively and the cell cycle was analyzed according 
to the procedure previously reported.[19] 
 
2.4. Drug loading of AT-MSCs with CisPt and caPt (II)-complex 
The drug loading of AT-MSCs was performed by priming the cells according to a standardized procedure that use high 
drug dosage as previously described.[29] Briefly, subconfluent cultures (2 × 104 cells/cm2) were exposed to 75 µM CisPt 
or CaPt (II)-complex  for 24 hours. Then, the cells were washed twice with PBS, detached with trypsin and washed twice 
in Hank’s solution (HBSS, Euroclone UK). 5x105 drug-primed cells (AT-MSCs/CisPt, AT-MSCs/ caPt (II)-complex) were 
then seeded in a 25 cm2 flask in 3 ml of IMDM with 10% FBS and 2 mM L-glutamine (Euroclone, UK) to release the 
drug. After 24 hours, conditioned media (CM), (CM 24h/CisPt, CM 24h/ caPt (II)-complex) were collected and tested 
in vitro for their anti-proliferative activity on CFPAC-1 cells (used as standard assay). Conditioned Media from unprimed 
MSCs were used as control. To determine the amount of drug internalized, 5x105 cells collected after the uptaking phase 
were lysed by three sonication cycles of 0.4 second pulse cycle and 30% amplitude each (Labsonic U Braun). Lysates 
from CisPt and caPt(II) primed cells (LYS/CisPt, LYS/caPt (II)-complex) and unprimed AT-MSCs were tested for their 
anti-proliferative activity. 
 
2.5. In vitro anti-proliferative assay of CM and LYSATE of AT-MSCs loaded with CisPt or caPt (II)-
complex 
The inhibitory effect of CM and cell lysates from drug loaded AT-MSCs were evaluated on CFPAC-1 proliferation by the 
MTT assay[29, 32] and the inhibitory concentration IC50 was determined according to the Reed and Muench 
formula.[31] The anti-tumoral activity of CM 24h/CisPt, CM 24h/ caPt (II)-complex, LYS/CisPt, LYS/caPt (II)-complex 
were compared to that of the pure drugs (CisPt, caPt (II)-complex) alone and expressed as drug equivalent concentration 
(DEC), according to the following algorithm: DEC (µg/ml) = IC50 Drug(µg/ml) × 100/ IC50 CM or LYS (μl/well). The 
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IC50 Drug is the concentration (µg/ml) of pure drug able to inhibit CFPAC-1 proliferation by 50%; IC50CM or LYS is the 
volume (μl/well) of CM or LYS inhibiting CFPAC-1 proliferation by 50%. To evaluate the drug released by a single primed 
cell (CDR = cell drug release), an arbitrary internal parameter based on the ratio between the DEC and the number of 
seeded cells [CDR (pg/cell) = DEC (ng/ml) × 103 × CM or LYS volume (ml)/ number of seeded cells] was used. 
 
2.6. Determination of Pt concentration in cell lysate (LYS) and in Conditioned Medium (CM) from 
drug loaded AT-MSCs 
Both the lysates (LYS/cisPt, LYS/caPt (II)-complex) and the conditioned media (CM 24 h/Cis-Pt, CM 24h/ caPt (II)-
complex) were dissolved in 1% HNO3. Platinum was quantified by inductively coupled plasma mass spectrometry (ICP-
MS) (BRUKER aurora M90 ICP-MS, MA, USA) according the previously described method.[33, 34] Cellular metal levels 
were expressed as the mean of three independent determinations as µg Pt per L of lysate or medium. The amount of Pt 
was transformed into caPt(II)-complex or CisPt, through these formula: caPt(II)-complex or CisPt = (Pt g/L) / MW Pt 
(g/moli) * MW caPt(II)-complex or CisPt. The concentration found (ng/ml) of caPt(II)-complex or CisPt was then 
evaluated as picoMolar per single AT-MSCs. 
 
2.7. Anti-angiogenic potential of CaPt(II)-Complex and CisPt 
To assess the anti-angiogenic potential of CaPt(II)-complex and CisPt, we investigated their inhibitory activity on 
Human Umbilical Vein Endothelial Cells (HUVECs) (LONZA Walkersville, MD. USA). HUVECs were routinely 
maintained in EGM bullet kit (LONZA Walkersville, MD. USA) plus 10% FBS. HUVECs proliferation assay was 
performed as previously described.[35] Briefly, HUVECs were harvested from culture flasks by trypsin. After enzyme 
inactivation and centrifugation, cells were re-suspended in EGM medium (LONZA Walkersville, MD. USA) +0.2% BSA 
and counted. To evaluate the growth response to CaPt(II)-complex and CisPt, 0.5 ml of HUVECs (104 cells) were seeded 
into a 24-multiwell plate (Corning, NY, USA) coated with collagen type I. After adhesion, medium was aspirated and 
replaced with EGM control medium +10% FBS (CTRL) supplemented or not with different concentrations of CaPt(II)-
complex and CisPt (from 1 to 40µM). Experiments were repeated using positive control growth medium consisted in 
EGM Bullet kit complete medium which produce a potent increment of HUVECs proliferation.  After 72h, the cells were 
washed, fixed and stained. Cells were counted with a calibrated ocular eyepiece in 10 different fields (400x 
magnification). Every test was run in triplicate. To test the effect of CaPt(II)-complex and CisPt on HUVECs tube 
formation, we used growth factor reduced-matrigel assay (Sigma) as described by Kleinman et al.[36] Briefly, around 
50µl of matrigel was placed into cold (4 °C) 96-multiwell plate (Corning, NY, USA) at 37 °C for 30 min until jellification. 
HUVECs were then seeded on matrigel at a concentration of 104 cells/well in 50µl of EGM growth medium (1:1) in 
presence or absence of different µM concentration of CaPt(II)-complex and CisPt. After 24 h, the number of HUVEC 
tube formations were counted with an inverted microscope (10x magnification) and reported as n° of tube 
structures/field. HUVECs proliferation and tube formation experiments were repeated to evaluate the stability of 
CaPt(II)-complex and CisPt. The drugs once diluted in the CTRL medium or in EGM Bullet kit complete medium were 
kept for 24-72 h at 37 °C before applying to the HUVECs. 
 
2.8. Statistical analysis 
Data are expressed as average ± standard deviation (SD). Differences between mean values were evaluated according to 
Student’s t-test performed by GRAPHPADINSTAT program (GraphPad Software Inc., San Diego, CA, USA). p values ≤ 
0.05 were considered statistically significant. The linearity of response and the correlation were studied using regression 
analysis, by Excel 2013 software (Microsoft, Inc.) 
 
3. Results and Discussion 
3.1. In vitro anticancer activity of CisPt and caPt (II)-complex 
The activity of CisPt and caPt(II)-complex, evaluated in vitro against three human cancer cell lines (pancreatic 
carcinoma CFPAC-1, glioblastoma U87 and mesothelioma NCI-H28), showed a dose-response kinetics of inhibition with 
a significant coefficient of correlation (R2) (Figure 1). However, against CFPAC-1 proliferation, CisPt was significantly 
(p<0.01) more active (IC50 = 9.64 ± 5.10 µM) than caPt(II)-complex (IC50= 21.25 ± 6.68 µM). A significant higher activity 
(p>0.05) of caPt(II)-complex was seen both against NCI-H28 cells (IC50 = 19.37 ± 9.57 μM versus 34.66 ± 7.65 μM for 
CisPt) and against U87 MG (IC50 = 19.85 ± 0.97 μM versus 54.14 ± 3.19 for CisPt). 
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Figure 1: In vitro anticancer activity of CisPt and caPt (II)-complex: The effect of increasing concentrations of caPt(II)-complex or CisPt 
was evaluated by a 7-day antiproliferation MTT assay on different tumor cell lines. A: pancreatic adenocarcinoma CFPAC-1; B: mesothelioma NCIH28; 
C: glioblastoma U87MG. The effect was expressed as a percentage of the optical density measured in cultures that did not receive drugs (100% 
proliferation). Linear regression with R2 value was reported. Histogram and box D report the IC50 values are expressed as mean ± standard deviation 
(SD) of “n” independent experiments. The means were compared by Student’s t-test (*p < 0.05). 
3.2. Anti-angiogenic potential of caPt(II)-complex and CisPt  
It has been shown that CisPt has some anti-angiogenic potential.[37] In order to verify whether also caPt (II)-complex 
could have anti-angiogenic activities in vitro, we investigated their effect on HUVECs proliferation and tube-structures 
formation on matrigel. To this end, CisPt and caPt (II)-complex were diluted in CTRL medium or in EGM-bullet kit 
medium and then tested on HUVECs to evaluate anti-proliferative activity at 72 h incubation. Under our experimental 
conditions, as shown in Figure 2, the addition of 10 to 30 µM of CisPt diluted in CTRL medium reduced significantly 
HUVEC proliferation (Figure 2A), caPt(II)-complex behaved similarly but was less effective at 10 µM concentration. 
Inhibition of HUVECs proliferation by CisPt was even more evident when experiments were repeated by culturing 
HUVECs in EGM-bullet kit medium which strongly enhance endothelial growth. In this case the addition of caPt(II)-
complex was effective as well as CisPt. The activity of CisPt and caPt(II)-complex to inhibit capillary-like tube formations 
on matrigel was practically similar at each tested concentration (Figure 2B). When proliferation and tube-structures 
formation assay were repeated upon pre-incubating at 37 °C for 72 h both CisPt and caPt(II)-complex diluted in EGM 
bullet kit medium, we found that caPt(II)-complex maintained completely its inhibitory activity, in contrast to CisPt that 
lost its efficacy to inhibit both HUVECs proliferation (Figure 2C) and cords formations (Figure 2D). These data 
suggested that caPt(II)-complex and CisPt have a similar anti-angiogenic activity, however caPt(II)-complex is a very 
stable molecule in contrast to CisPt.  
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Figure 2. Anti-Angiogenic properties of CisPt and caPt(II)-complex. The anti-angiogenic properties of CisPt and caPt(II)-complex were 
investigated by adding µM concentrations of both compounds diluted either in CTRL medium or in EGM- bullet kit medium. In (A) the inhibitory 
effect of CisPt and caPt(II)-complex on HUVECs proliferation. In (B) the quantification of cord formations on matrigel by HUVECs under the influence 
of CisPt and caPt(II)-complex at 24 h. To note that caPt(II)-complex and CisPt diluted in EGM-bullet kit medium a medium that stimulate both 
HUVECs proliferation and cords formations, demonstrated a similar anti-angiogenic efficacy. In (C) and (D) the effect on HUVECs proliferation and 
cords formation respectively, after pre-incubating at 37 °C for 72 h of CisPt and caPt(II)-complex diluted in EGM bullet kit medium. To note, that 
CisPt lost completely its anti-angiogenic activity, whereas it was maintained by caPt(II)-complex compound (* p<0.05; ** p<0.01 vs CTRL medium 
or EGM-bullet kit medium; °° p<0.01 vs CTRL medium). 
3.3. Mesenchymal stromal cells (MSCs) sensitivity to CisPt and caPt(II)-complex 
The two compounds were tested both for their cytotoxic and antiproliferative activity on AT MSCs (Figure 3A-B). As 
evidenced by the linear regression analysis, by considering the cytotoxicity at 24 h, MSCs showed to have a similar 
sensitivity both to caPt(II)-complex and CisPt (91.1 ± 29.4 µM versus 82.2 ± 54.2 µM). On the contrary, in the 
antiproliferation test the IC50 for the two drugs were significantly (p< 0.05) different being 69.9 ± 5.5 µM for caPt(II)-
complex and 11.4 ± 5.2 µM for CisPt. Figure 3C reported the cell cycle of AT-MSCs treated for 24 h with the two 
molecules at 75 µM showing any significant modification of the cell cycle. 
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Figure 3. Mesenchymal stromal cells (AT-MSCs) sensitivity to CisPt and caPt(II)-complex and cell cycle analysis: A: The cytotoxic 
activity was evaluated after 24 h of treatment with different concentrations of caPt(II)-complex or CisPt (from 0 to 200 μM) and expressed as cell 
viability (% of control cells). Linear regression with R2 value was reported. The box reports the IC50 values B: The effect of increasing concentrations 
(from 0 to 85 µM) of caPt(II)-complex or CisPt was also evaluated by a 7-day anti-proliferation assay. The effect is expressed as percentage of the 
optical density measured in cultures that did not receive drugs (100% proliferation). Linear regression with R2 value was reported. IC50 values are 
expressed as mean ± standard deviation (SD) of four independent experiments. C: The histogram shows the effects of caPt(II)-complex or CisPt 
treatments (75 µM) on AT-MSCs after 24 h of treatment. The percentages of cells counted in each different cell phase (G0/G1, S and G2/M) are 
reported and compared to those found in untreated cells (CTRL). The values are expressed as mean ± standard deviation (SD) of eight independent 
experiments.  
3.4. Stability of CisPt and caPt(II)-complex to treatment at 37 °C 
Both CisPt and caPt(II)-complex were studied for their stability following the incubation at 37 °C in the complete cell 
culture medium both in the absence and the presence of a monolayer of MSCs. The stability has been evaluated by 
determining the dose response inhibiting kinetics against CFPAC-1 proliferation (Figure 4A-D). After 24 h of 
incubation CisPt completely lost its anticancer activity under both two incubation conditions. caPt(II)-complex 
maintained its ability to inhibit cancer cell proliferation with a dose response kinetics like that of the fresh drug both if 
incubated in the absence and presence of MSCs monolayer. By comparing IC50 of the caPt(II)-complex no significant 
difference (p<0.05) was observed (Figure 4E-F).
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Figure 4: Stability of Cis-Pt and caPt (II)-complex at 37°C of incubation. The effect of increasing concentrations of caPt(II)-complex (A and 
C) or CisPt (B and D) was evaluated by a 7-day antiproliferation MTT assay on CFPAC-1. Fresh prepared drugs or drugs incubated for 24 h or 9 days 
at 37 °C were tested. Incubation was performed in medium and in the presence of AT-MSCs. The histogram E and box F report the IC50 values 
expressed as mean ± standard deviation (SD) of four independent experiments. 
3.5. Uptake/release of CisPt and caPt (II)-complex by AT-MSCs 
Biological dosage: the anti-cancer activity of cell lysate (LYS/CisPt, LYS/caPt (II)-complex) and the corresponding 
conditioned medium (CM 24h/CisPt, CM 24h/caPt (II)-complex) obtained from drug-primed MSCs were tested against 
our standard laboratory cancer cell line CFPAC-1 (Figure 5A-B). Both CM 24h/CisPt and CM 24h/caPt (II)-complex 
did not express activity on the cancer proliferation until the dosage of 100 µl/well tested.  
Analytical dosage: to evaluate the amount of the two drugs uptaken and released by MSCs an ICP spectrometry 
analysis was performed both on cell lysates and CM. MSCs were able to incorporate both the drugs in amounts that do 
not differ statistically (2.3 ± 0.11 pM/cell for caPt(II)-complex versus 1.63 ± 0.7 pM/cell for CisPt). The analysis of 
conditioned medium showed a release of 0.72 ± 0.14 pM/cell for caPt(II)-complex and 1.55 ± 0.97 for CisPt. By 
considering the drug released at 24 h as percentage of the amount incorporated, it is evident that the drug loaded MSCs 
released the 35.7% of the caPt(II)-complex and the 95 % of the CisPt. By mimicking a possible in vivo treatment “in situ” 
of a tumor mass (of about 1 cm3) with drug loaded MSCs (Figure 5D) we can estimate that for delivering caPt(II)-
complex to a concentration near to 3 x IC50 value, we need about 24 x 106 drug loaded MSCs. 
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Figure 5: Uptake/release of CisPt and caPt(II)-complex by AT-MSCs: The activity of cell lysates (LYS) and 24 h conditioned media (CM) 
from AT-MSCs loaded with caPt(II)-complex (A) (LYS/caPt(II)-complex; CM 24 h/caPt(II)-complex) or with CisPt (B) (LYS/CisPt; CM 24 h/ Cispt) 
was evaluated against CFPAC-1 proliferation in comparison to the pure drugs. The concentration-dependent inhibition was normalized on the 
inhibition produced by lysate from unloaded AT-MSCs. Linear regression with R2 value was reported. The histogram C reports drug uptake and release 
values expressed at pM/cell through inductively coupled plasma mass spectrometry (ICP-MS). The values are expressed as mean ± standard deviation 
(SD) of four independent experiments. The means were compared by Student’s t-test (*p < 0.05). Figure D mimics an “in situ” treatment of 
glioblastoma tumor mass with drug loaded MSCs. 
Our results evidenced that caPt(II)-complex exerts a remarkable anticancer activity in vitro against the three cancer 
cells lines studied (Figure 1). While the activity against PAC cells exerted by caPt(II)-complex is lower than that exerted 
by CisPt a significant (p<0.05) higher activity of this new molecule was evidenced both against MPM and GBM. It is 
known that, beside the anticancer activity, for an optimal chemotherapeutic action is very important the solubility and 
the stability influencing the management of the molecules and increasing or reducing their action. Unfortunately, 
platinum-based drugs have very limited solubility in culture medium and also can suffer degradation process by pH 
modification and temperature.[23] Concerning their stability, our findings evidenced that caPt(II)-complex is a very 
stable compound if compared to CisPt. The treatment of the two drugs at 37 °C demonstrated that whereas CisPt lost its 
anticancer activity after only 24 h, caPt(II)-complex maintained its unaltered activity after a long time of incubation 
(Figure 4). In addition, although GBM angiogenic activity is not the primary target CisPt chemotherapy, we here 
confirm that CisPt can inhibit angiogenesis.[37] However, while CisPt lost rapidly its efficacy after pre-incubation at 37 
°C, caPt(II)-complex maintained its capability to inhibit both HUVECs proliferation and cords formation even after 72 
h incubation (Figure 2). The cancer activity is maintained also if caPt(II)-complex is incubated in the presence of a 
monolayer of MSCs confirming that the molecule did not suffer modification due to cell metabolism and significant 
variation of pH of the culture medium produced by the cell growth (Figure 4E). Our results on CisPt agreed with 
literature data showing that this molecule is rapidly and dramatically degraded by pH changes and temperature.[22] 
The finding concerning the high stability of caPt(II)-complex is very important in order to apply the procedure of drug 
loading previously set up in our laboratory[18] that is based on the MSCs treatment for 24 h with high concentration of 
drug. To better set up the drug loading procedure, we also tested the sensitivity of MSCs to both caPt(II)-complex and 
CisPt because the cell viability and function during the procedure is important for an optimal drug incorporation. The 
results (Figure 3) demonstrated the same sensitivity of AT-MSCs to the cytocidal effect of the two molecules that 
confirmed our previous data on smooth muscle cells.[14] However, AT-MSCs were significantly more resistant (or less 
sensitive) to the antiproliferative action of caPt(II)-complex than to that exerted by CisPt. The reason of this difference 
is not clear. In fact, the cell cycle remained unaffected after the cell treatment with 75 µM concentration of the drugs 
that, on the contrary, produced a significant different inhibition of cell proliferation (Figure 3C).   
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Of course, this aspect needs to be better investigated because it seems to be related to a different biological response of 
MSCs to the two drugs concerning the connection between the mechanisms of proliferation and cell death pathways in 
mesenchymal stromal cells. By applying the standard procedure of MSCs drug loading, the efficiency of the MSCs 
incorporation of the two drugs was evaluated by testing cell lysates. The amount of drug released was measured in the 
conditioned medium of drug loaded MSCs sub-cultured for 24 h. The analytical data on lysates confirmed a similar 
efficient incorporation of both the molecules by AT-MSCs (Figure 3C) but a different capability of the cells to release 
them. The different behavior of the cells in releasing the drugs is not clear but it probably due to fact that caPt(II)-
complex was not able to interact with nuclear DNA as previously reported.14 This is also supported by the observation 
(not reported here) that CisPt loaded MSCs, differently from caPt(II)-complex loaded MSCs, had more difficulty to 
adhere to the substrate when sub-cultured to evaluate the drug release. This could be related to a pre-apoptotic program 
that allowed the cells to release higher amounts of incorporated drug. As reported in the results, both lysates and CM 
tested did not express in vitro any anticancer activity that is explained by the amount of drug that in our system the cells 
can carry and delivery. In fact, based on the analytical data, we calculated that the maximal amount (100 µl/well) tested 
of lysate or CM contains 2 µM of the drugs that is a too low concentration inadequate to exert on the cancer cells a 
detectable inhibition (being the IC50 of 9.64 ± 5.1 µM).  
4. Conclusion 
In conclusion, our data report for the first time that caPt(II)-complex is a molecule that in vitro is more active than CisPt 
against two very aggressive tumors: MPM and GBM. The high stability of caPt(II)-complex other than favoring it 
possible clinical management suggests also a possible application for loading MSCs to use for advanced cell therapy 
based on cells mediated drug delivery. Loco-regional treatment of tumor with drug loaded MSCs could contribute to 
increase the selectivity and efficacy of chemotherapy and at the same time to reduce significantly the toxicity of CisPt 
following systemic treatment. Large scale production of drug loaded MSCs are in progress in our laboratory to manage 
in vivo preclinical studies that will help to understand if it will be possible to develop an advanced cell therapy to apply 
as adjuvant in traditional chemo-surgical and radiotherapy. 
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